Evotec/$EVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Ticker
$EVO
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
4,766
ISIN
US30050E1055
Website
Evotec Metrics
BasicAdvanced
$1.5B
-
-$1.37
1.09
-
Price and volume
Market cap
$1.5B
Beta
1.09
52-week high
$5.48
52-week low
$2.84
Average daily volume
139K
Financial strength
Current ratio
2.028
Quick ratio
1.749
Long term debt to equity
45.803
Total debt to equity
52.482
Interest coverage (TTM)
-7.04%
Profitability
EBITDA (TTM)
1.368
Gross margin (TTM)
13.62%
Net profit margin (TTM)
-26.26%
Operating margin (TTM)
-10.22%
Effective tax rate (TTM)
-5.04%
Revenue per employee (TTM)
$199,550
Management effectiveness
Return on assets (TTM)
-2.42%
Return on equity (TTM)
-20.51%
Valuation
Price to revenue (TTM)
0.801
Price to book
1.4
Price to tangible book (TTM)
2.12
Price to free cash flow (TTM)
-8.283
Free cash flow yield (TTM)
-12.07%
Free cash flow per share (TTM)
-50.47%
Growth
Revenue change (TTM)
1.50%
Earnings per share change (TTM)
128.61%
3-year revenue growth (CAGR)
6.66%
10-year revenue growth (CAGR)
23.77%
3-year earnings per share growth (CAGR)
30.40%
10-year earnings per share growth (CAGR)
43.89%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Bulls say / Bears say
Evotec's strategic partnership with Bristol Myers Squibb has expanded beyond oncology, triggering a $50 million payment and potentially leading to further milestone payments, indicating strong collaborative progress. (accesswire.com)
The company has initiated a 'Priority Reset' program aimed at enhancing operational efficiency and is on track to deliver an annualized adjusted EBITDA improvement of over €40 million, reflecting a commitment to sustainable profitable growth. (accesswire.com)
Evotec's collaboration with Novo Nordisk to support the manufacturing of stem cell-based therapies positions the company at the forefront of innovative treatment development, potentially opening new revenue streams. (reuters.com)
Bank of America Securities downgraded Evotec's price target from $4.50 to $3.00, maintaining an 'Underperform' rating due to underwhelming quarterly performance and a cautious market outlook. (investing.com)
The company reported a 5.8% year-over-year decline in revenue for Q3 2024, indicating challenges in maintaining growth momentum. (google.com)
Evotec's stock experienced a significant drop of 33% following a gloomy annual forecast, reflecting investor concerns over the company's future performance. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Evotec News
AllArticlesVideos
Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
Accesswire·2 weeks ago
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Accesswire·2 months ago
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.5B as of July 09, 2025.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of July 09, 2025.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of July 09, 2025.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.